Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 405-414

  Hohlfeld, J M ^a   Sharma, A ^b   Van Noord, J A ^c   Cornelissen, P J G ^b   Derom, E ^d   Towse, L ^b   Peterkin, V ^b   Disse, B ^b  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Zuyderland Medical Centre   (Netherlands)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

COPD; pharmacodynamics; pharmacokinetics; tiotropium HandiHaler ; tiotropium Respimat SMI

Indexed keywords

PLACEBO; RESPIMAT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; HOLTER MONITORING; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

COPD; PHARMACODYNAMICS; PHARMACOKINETICS; TIOTROPIUM HANDIHALER®; TIOTROPIUM RESPIMAT® SMI;

AGED; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SOLUTIONS; TREATMENT OUTCOME;

EID: 84898649762     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.215     Document Type: Article

References (22)

1. Celli BR, MacNee W,. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23 (6): 932-946. (Pubitemid 38807371)
2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/. Last accessed April 2011
3. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis. 2010; 5: 197-208.
4. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010; 104 (10): 1460-1472.
5. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005; 128 (3): 1168-1178. (Pubitemid 41324392)
6. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005; 143 (5): 317-326.
7. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359 (15): 1543-1554.
8. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C,. The efficacy of tiotropium administered via Respimat soft mist inhaler or HandiHaler in COPD patients. Respir Med. 2009; 103 (1): 22-29.
9. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J., 2002; 19 (2): 209-216. (Pubitemid 34162819)
10. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat soft mist inhaler vs. ipratropium pMDI in COPD. Respir Med. 2008; 102 (1): 32-41. (Pubitemid 350161846)
11. Hodder R, Price D,. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009; 4: 381-390.
12. Durham MC,. Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Proc (Bayl Univ Med Cent). 2004; 17 (3): 366-373.
13. van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ,. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002; 19 (4): 639-644. (Pubitemid 34285160)
14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16: 5-40.
15. American Thoracic Society. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995; 152 (3): 1107-1136.
16. Morais JA, Lobato MR,. The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol. 2010; 106 (3): 221-225.
17. Price D, Sharma A, Cerasoli F,. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol. 2009; 5 (4): 417-424.
18. Ichinose M, Fujimoto T, Fukuchi Y,. Tiotropium 5 microg via Respimat and 18 microg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010; 104 (2): 228-236.
19. SPIRIVA® Respimat®, summary of product characteristics. 2012. July 4, 2012.
20. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS,. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013; 68 (1): 48-56.
21. Karner C, Chong J, Poole P,. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 7: CD009285.
22. Singh S, Loke YK, Enright PL, Furberg CD,. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215.